Aprazer markets Ledikast, a drug used to treat Hepatitis C. It is produced by Natco Pharma and sold by Aprazer.
Ledikast is a medication that combines two antiviral medicines to treat Hepatitis C virus (HCV) infection. In people with HCV genotype 1, 4, 5, or 6, the fixed-dose combination (FDC) (ledipasvir + sofosbuvir) is advised based on the genotype of HCV.
Both ledipasvir and sofosbuvir are direct-acting antiviral (DAA) medicines that target the NS5A and NS5B proteins in HCV. These proteins are required for viral cell multiplication (RNA replication and virion assembly), which reduces viral cell burden in the system. After 12 weeks of therapy, the FDC delivers a sustained virologic response (SVR) of 93 percent to 99 percent.